Opioid Crisis

Supporting the mission and goals of National Fentanyl Awareness Day in 2025, including increasing individual and public awareness of the impact of fake or counterfeit fentanyl pills on families and young people.

The resolution increases public-health attention, awareness, and justification for enforcement against deadly counterfeit fentanyl pills—potentially reducing youth overdoses—but may shift resources toward policing, further stigmatize people who use drugs, and raise compliance costs for online commerce.

Expressing support for the designation of February 23, 2025, to March 1, 2025, as "National Fentanyl Awareness Week" and raising awareness of the negative impacts of fentanyl in the United States.

The bill increases attention to fentanyl's lethal risk and could strengthen prevention, testing, and enforcement coordination, but it also risks steering resources toward punitive border and law-enforcement responses and fueling fear that may undercut treatment, harm reduction, and civil liberties.

Designating August 21, 2026, as "Fentanyl Prevention and Awareness Day".

The resolution creates an annual National Fentanyl Awareness Day to boost public education and coordinated prevention efforts, but it is non-binding and risks encouraging enforcement-focused, stigmatizing approaches without providing funding for treatment or harm reduction.

Strengthening Sanctions on Fentanyl Traffickers Act of 2025

The bill strengthens U.S. tools to disrupt international synthetic-drug supply chains and gives law enforcement and financial actors clearer authority to block illicit flows, but it broadens reach and liability, raises compliance costs, and risks diplomatic and due-process consequences that could strain trade and complicate enforcement.

SAFE Act

The bill sharpens and speeds federal control and enforcement against fentanyl-related substances and creates scientific and procedural pathways for rescheduling and research, but it risks criminalizing legitimate research and low-level handlers, increases mandatory penalties that can widen disparities and incarceration costs, and could leave enforcement gaps for new synthetic opioids.